Bodal Chemicals Ltd

- No new expansion CAPEX is planned until business performance improves; current CAPEX (around Rs. 390 crore for benzene derivatives) to be completed within FY24. - All future cash flows post-CAPEX are planned to be used primarily for debt repayment. - Current gross debt stands at around Rs. 875 crore (Rs. 550 crore term debt + Rs. 325 crore working capital debt), with net debt about Rs. 800 crore. - Debt expected to be around Rs. 350 crore term debt by FY26 and working capital to remain at Rs. 300-350 crore. - Some non-core asset sale (land, factory in Ahmedabad valued at approx. Rs. 100 crore) is planned to reduce debt over the next 1 to 1.5 years. - Weighted average cost of debt is about 8.5%, with possible incremental increases of 0.5% due to rating changes. - No mention of equity fundraising during the call.

- The company has completed a major CAPEX for benzene derivatives of around Rs. 390 crores within the current year; most payments (about Rs. 30 crores) are pending. - No further CAPEX or expansion is planned for the next two years until business performance improves. - All future cash flows are expected to be utilized towards debt repayment rather than new capital investments. - The company is focusing on stabilizing and optimizing the newly set-up benzene derivatives plant with an installed capacity of 63,000 tons per annum, expecting significant revenue (~Rs. 320 crores) and better margins (12%-15%) from next year onwards. - Strategic actions include shutting down smaller, less profitable older units to save fixed overheads and improve margins. - The company is also evaluating non-core asset sales (including land and factory in Ahmedabad valued around Rs. 100 crores) to reduce debt.

- The company expects additional revenue of around Rs. 320 crores from the new benzene derivatives plant at optimum utilization by next year onwards. - Benzene derivatives segment aims to contribute roughly 25%-30% of overall topline with EBITDA margins of 12%-15%. - Capacity utilization for benzene derivatives is expected to ramp up to 50%-70% within 3-4 months and reach over 80% in subsequent months. - No major CAPEX planned for the next two years; generated cash flows will focus on debt repayment. - Dye intermediate revenue showed a 19% year-on-year growth in 9M FY24, indicating volume growth potential. - Caustic soda volumes grew by 25% in 9M FY24 despite price pressure; demand expected to remain healthy from FMCG, textile, and paper sectors. - Overall volumes and demand are gradually improving post multiple global headwinds, with December-January numbers better than previous quarters.

- Bodal Chemicals expects revenue growth from the new benzene derivatives business, anticipating Rs. 320 crore additional revenue at optimum utilization with 12%-15% EBITDA margins. - Current EBITDA margins of 7%-8% are expected to improve to around 10%-13% over the next few years with new business addition and cost rationalization. - The company aims to gradually close smaller, less profitable units to reduce fixed overheads and improve margins. - No major CAPEX is planned until business performance improves; free cash flows will be directed towards debt reduction. - By FY26, term debt is expected to be around Rs. 350 crore, and working capital to remain at Rs. 300-350 crore levels, reflecting improved financial health. - Overall, Bodal targets to elevate EBITDA margins to around 12%-13%, up from recent lows of 7%-8%, with steady long-term profitability improvement.

The transcript provided does not specifically mention details about the current or expected order book or pending orders for Bodal Chemicals Limited. However, some relevant insights related to business and demand include: - Company is witnessing a gradual pickup in volumes but demand is not aggressive yet. - International demand and volumes have normalized after a de-stocking phase of several quarters. - Benzene derivatives business is expected to add additional revenue of around Rs. 320-330 crores at optimum utilization. - The company is focusing on debt repayment and not planning any immediate CAPEX until business performance improves. - No explicit commentary on current order book size or pending orders was given during the call. Hence, no concrete figure or direct reference to the order book or pending orders is provided in the transcript.